Selvita SA (PL:SLV)
:SLV
Top Page
Selvita SA
(SLV)
Select Model
Select Model
Rating:51Neutral
Price Target:
zł34.00
▼(-26.88% Downside)
Action:N/ADate:09/14/25
Selvita SA's overall stock score of 51 is primarily driven by mixed financial performance, with strong cash flow growth offset by profitability challenges and a negative net profit margin. Valuation concerns due to a negative P/E ratio further weigh on the score, while neutral technical analysis adds little directional impact.
Selvita SA (SLV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł537.82M
Dividend YieldN/A
Average Volume (3M)40.05K
Price to Earnings (P/E)975.1
Beta (1Y)0.75
Revenue Growth14.10%
EPS Growth-99.00%
CountryPL
Employees969
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.40
Shares Outstanding18,355,474
10 Day Avg. Volume21,446
30 Day Avg. Volume40,050
Financial Highlights & Ratios
PEG Ratio-8.60
Price to Book (P/B)2.46
Price to Sales (P/S)2.18
P/FCF Ratio13.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.01
Revenue Forecast (FY)zł413.28M
Selvita SA Business Overview & Revenue Model
Company Description
Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug di...
How the Company Makes Money
Selvita makes money through multiple revenue streams. Primarily, the company generates revenue by providing contract research services to other pharmaceutical and biotechnology companies. These services include drug discovery, preclinical developm...
Selvita SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
65
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 364.47M | 342.01M | 346.72M | 360.68M | 310.92M |
| Gross Profit | 19.37M | 267.82M | 275.56M | 292.62M | 251.26M |
| EBITDA | 61.76M | 55.30M | 125.61M | 75.39M | 52.43M |
| Net Income | 813.00K | -6.10M | 69.88M | 30.31M | 14.90M |
Balance Sheet | |||||
| Total Assets | 597.77M | 642.09M | 636.26M | 584.91M | 466.59M |
| Cash, Cash Equivalents and Short-Term Investments | 24.22M | 22.51M | 52.97M | 76.17M | 96.98M |
| Total Debt | 169.57M | 218.54M | 224.75M | 212.97M | 179.80M |
| Total Liabilities | 276.05M | 320.21M | 309.19M | 311.75M | 261.04M |
| Stockholders Equity | 321.73M | 321.88M | 327.07M | 262.18M | 196.87M |
Cash Flow | |||||
| Free Cash Flow | 57.24M | 45.36M | 5.05M | -26.16M | 59.95M |
| Operating Cash Flow | 64.32M | 64.07M | 78.98M | 75.43M | 87.47M |
| Investing Cash Flow | -8.65M | -36.87M | -65.21M | -79.79M | -164.33M |
| Financing Cash Flow | -53.96M | -57.34M | -30.97M | -5.67M | 66.82M |
Selvita SA Technical Analysis
Negative
46.50
Price Trends
39.69
Negative
42.08
Negative
38.44
Negative
Market Momentum
-2.96
Positive
12.04
Positive
4.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:SLV, the sentiment is Negative. The current price of 46.5 is above the 20-day moving average (MA) of 35.35, above the 50-day MA of 39.69, and above the 200-day MA of 38.44, indicating a bearish trend. The MACD of -2.96 indicates Positive momentum. The RSI at 12.04 is Positive, neither overbought nor oversold. The STOCH value of 4.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:SLV.
Selvita SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | zł537.82M | 975.15 | -1.25% | ― | 14.10% | -99.00% | |
| ― | zł32.08M | -7.33 | 111.82% | ― | ― | ― | |
51 Neutral | zł1.09B | 77.86 | ― | 0.43% | 47.79% | ― | |
44 Neutral | zł541.01M | -6.19 | -110.42% | ― | 15.45% | -25.81% | |
42 Neutral | zł444.27M | -4.87 | -109.96% | ― | -40.45% | 27.53% |
* Healthcare Sector Average
PL:SLV
Selvita SA
30.90
-0.40
-1.28%
PL:PUR
Pure Biologics SA
―
―
―
PL:RVU
Ryvu Therapeutics SA
23.55
-0.95
-3.88%
PL:CLN
Celon Pharma SA
21.10
-3.80
-15.26%
PL:CTX
Captor Therapeutics SA
80.80
48.80
152.50%
PL:MOC
OncoArendi Therapeutics SA
5.45
-2.60
-32.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.